GPP
NKTR icon

Great Point Partners’s Nektar Therapeutics NKTR Stock Holding History

Great Point Partners’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-6,667
Closed -$539K – 39
2022
Q1 		$539K Sell
6,667
-6,926
-51% -$1.03M 0.13% 28
2021
Q4 		$2.75M Buy
+13,593
New +$2.95M 0.61% 32

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Great Point Partners's NKTR Position: Q2 2026 in Review

Great Point Partners reduced its Nektar Therapeutics (NKTR) stake by 45% in Q2 2026, selling an estimated $10.4M and leaving 175,000 shares worth $12.2M. The position accounts for 2.31% of the portfolio, ranked #19.

Great Point Partners first reported a position in NKTR in Q3 2019 and has held it in 8 quarters since. The position peaked at $38.7M in Q3 2019. 240 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Great Point Partners held 175,000 shares of Nektar Therapeutics worth $12.2M as of Q2 2026.
  • Great Point Partners sold 141,453 Nektar Therapeutics shares in Q2 2026, an estimated $10.4M.
  • Nektar Therapeutics made up 2.31% of Great Point Partners's portfolio in Q2 2026, its #19 holding.
  • Great Point Partners first reported a position in Nektar Therapeutics in Q3 2019 and has held it in 8 quarters since.
  • Great Point Partners's Nektar Therapeutics position peaked at $38.7M in Q3 2019.
  • 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Great Point Partners's 13F filing for Q2 2026, filed 14 Aug 2026.